BIOS.ST
Bioservo Technologies AB (publ) [BIOS.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIOS.ST Stock Summary
In the News
BIOS.ST Financial details
Company Rating
Sell
Market Cap
1.41M
Income
-46.94M
Revenue
11.24M
Book val./share
1.36
Cash/share
0.67
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
-0.02
Forward P/E
-
PEG
0.01
P/S
0.15
P/B
0.01
P/C
0.02
P/FCF
-0.03
Quick Ratio
2.01
Current Ratio
3.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.81
EPS next Y
-
EPS next Q
-
EPS this Y
22.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.46%
Revenue last 5Y
7.53%
Revenue Q/Q
246.13%
EPS Q/Q
-19.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-46%
ROE
-69%
ROC
-0.65%
Gross Margin
31%
Oper. Margin
-415%
Profit Margin
-415%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.011-2.39
52W High
-
52W Low
-
RSI
22
Rel Volume
2.76
Avg Volume
2.51M
Volume
6.93M
Perf Week
-8.05%
Perf Month
-68%
Perf Quarter
-
Perf Half Y
-95.94%
-
-
-
-
Beta
0.796
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.016
Change
-10.11%
BIOS.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.63 | 0.93 | 0.8 | 0.43 | 0.49 | |
| Net income per share | -2.62 | -2.34 | -1.81 | -2.09 | -2.56 | |
| Operating cash flow per share | -1.59 | -2.61 | -1.14 | -2.07 | -2.56 | |
| Free cash flow per share | -2.03 | -2.71 | -1.22 | -2.18 | -2.62 | |
| Cash per share | 2.4 | 5.73 | 3.62 | 3.11 | 1.27 | |
| Book value per share | 3.77 | 7.57 | 4.29 | 3.78 | 1.9 | |
| Tangible book value per share | 2.32 | 6.29 | 3.6 | 3.31 | 1.6 | |
| Share holders equity per share | 3.77 | 7.57 | 4.29 | 3.78 | 1.9 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 97.85M | 139.12M | 250.58M | 169.2M | 37.82M | |
| Enterprise value | 72.29M | 82.19M | 198.02M | 117.68M | 12.81M | |
| P/E ratio | -3.51 | -5.98 | -9.52 | -4.88 | -0.75 | |
| Price to sales ratio | 14.59 | 15.01 | 21.49 | 23.83 | 3.92 | |
| POCF ratio | -5.78 | -5.37 | -15.11 | -4.92 | -0.75 | |
| PFCF ratio | -4.54 | -5.16 | -14.09 | -4.68 | -0.73 | |
| P/B Ratio | 2.44 | 1.85 | 4.02 | 2.7 | 1.01 | |
| PTB ratio | 2.44 | 1.85 | 4.02 | 2.7 | 1.01 | |
| EV to sales | 10.78 | 8.87 | 16.98 | 16.57 | 1.33 | |
| Enterprise value over EBITDA | -3.83 | -4.24 | -8.89 | -3.81 | -0.27 | |
| EV to operating cash flow | -4.27 | -3.17 | -11.94 | -3.42 | -0.25 | |
| EV to free cash flow | -3.35 | -3.05 | -11.14 | -3.25 | -0.25 | |
| Earnings yield | -0.29 | -0.17 | -0.11 | -0.2 | -1.34 | |
| Free cash flow yield | -0.22 | -0.19 | -0.07 | -0.21 | -1.37 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.35 | 2.94 | 2.36 | 1.67 | 0.53 | |
| Current ratio | 3.39 | 11.34 | 7.54 | 6.2 | 3.28 | |
| Interest coverage | -3.27K | -4.65K | 0 | -3.15K | -5.06K | |
| Income quality | 0.76 | 1.11 | 0.63 | 0.99 | 1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.7 | 1.88 | 0.93 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.39 | 0.31 | 0.52 | 0.23 | |
| Intangibles to total assets | 0.31 | 0.16 | 0.14 | 0.11 | 0.11 | |
| Capex to operating cash flow | 0.27 | 0.04 | 0.07 | 0.05 | 0.02 | |
| Capex to revenue | -0.69 | -0.11 | -0.1 | -0.25 | -0.11 | |
| Capex to depreciation | -1.41 | -0.27 | -0.3 | -0.44 | -0.35 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 14.91 | 19.97 | 13.22 | 13.34 | 10.45 | |
| ROIC | -0.69 | -0.31 | -0.42 | -0.55 | -1.36 | |
| Return on tangible assets | -0.8 | -0.34 | -0.43 | -0.53 | -1.08 | |
| Graham Net | 1.57 | 5.64 | 3.19 | 3 | 1.03 | |
| Working capital | 24.13M | 62.01M | 52.26M | 54.92M | 32.3M | |
| Tangible asset value | 24.75M | 62.55M | 52.3M | 54.93M | 31.55M | |
| Net current asset value | 24.13M | 62.01M | 51.94M | 54.73M | 31.36M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 1.66M | 1.98M | 4.37M | 6.82M | |
| Average payables | 2.07M | 2.03M | 2.19M | 4.08M | 5.96M | |
| Average inventory | 1.83M | 3.89M | 4.19M | 4.48M | 9.28M | |
| Days sales outstanding | 0 | 130.97 | 19.87 | 417.08 | 208.83 | |
| Days payables outstanding | 1.03K | 161.72 | 141.37 | 397.43 | 301.34 | |
| Days of inventory on hand | 1.17K | 463.78 | 172.77 | 414.21 | 606.93 | |
| Receivables turnover | 0 | 2.79 | 18.37 | 0.88 | 1.75 | |
| Payables turnover | 0.35 | 2.26 | 2.58 | 0.92 | 1.21 | |
| Inventory turnover | 0.31 | 0.79 | 2.11 | 0.88 | 0.6 | |
| ROE | -0.69 | -0.31 | -0.42 | -0.55 | -1.35 | |
| Capex per share | -0.44 | -0.11 | -0.08 | -0.11 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.1 | 0.06 | 0.16 | 0.04 | 0.15 | |
| Net income per share | -0.57 | -0.72 | -0.33 | -0.42 | -0.34 | |
| Operating cash flow per share | -0.79 | -0.61 | -0.45 | -0.34 | -0.54 | |
| Free cash flow per share | -0.8 | -0.61 | -0.45 | -0.35 | -0.55 | |
| Cash per share | 0.67 | 1.13 | 0.42 | 1.42 | 0.67 | |
| Book value per share | 3.28 | 1.69 | 0.98 | 1.7 | 1.36 | |
| Tangible book value per share | 2.95 | 1.43 | 0.78 | 1.51 | 1.36 | |
| Share holders equity per share | 3.28 | 1.69 | 0.98 | 1.7 | 1.36 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 54.98M | 42.36M | 42.77M | 16.4M | 12.8M | |
| Enterprise value | 42.25M | 17.35M | 30.72M | -24.01M | -6.09M | |
| P/E ratio | -1.28 | -0.67 | -1.14 | -0.34 | -0.33 | |
| Price to sales ratio | 29.18 | 33.67 | 9.25 | 13.66 | 3.08 | |
| POCF ratio | -3.66 | -3.15 | -3.35 | -1.72 | -0.84 | |
| PFCF ratio | -3.62 | -3.14 | -3.31 | -1.67 | -0.82 | |
| P/B Ratio | 0.88 | 1.13 | 1.52 | 0.34 | 0.33 | |
| PTB ratio | 0.88 | 1.13 | 1.52 | 0.34 | 0.33 | |
| EV to sales | 22.43 | 13.79 | 6.64 | -19.99 | -1.46 | |
| Enterprise value over EBITDA | -4.25 | -1.24 | -3.44 | 2.11 | 0.65 | |
| EV to operating cash flow | -2.82 | -1.29 | -2.41 | 2.52 | 0.4 | |
| EV to free cash flow | -2.78 | -1.29 | -2.38 | 2.45 | 0.39 | |
| Earnings yield | -0.2 | -0.37 | -0.22 | -0.73 | -0.76 | |
| Free cash flow yield | -0.28 | -0.32 | -0.3 | -0.6 | -1.21 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.28 | 1.79 | 1.35 | 3.54 | 2.03 | |
| Current ratio | 3.15 | 3.28 | 2.85 | 3.17 | 4.35 | |
| Interest coverage | -1.19K | -14.44K | -1.88K | -626.21 | 0 | |
| Income quality | 1.4 | 0.84 | 1.36 | 0.8 | 1.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.86 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 1.73 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.16 | 0.11 | 0.14 | 0.08 | 0.11 | |
| Capex to operating cash flow | 0.01 | 0 | 0.01 | 0.03 | 0.02 | |
| Capex to revenue | -0.11 | -0.03 | -0.04 | -0.22 | -0.08 | |
| Capex to depreciation | -0.26 | -0.08 | -0.37 | -0.52 | -0.72 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.46 | 5.23 | 2.69 | 4.01 | 3.24 | |
| ROIC | -0.17 | -0.39 | -0.33 | -0.25 | -0.25 | |
| Return on tangible assets | -0.33 | -0.34 | -0.26 | -0.19 | -0.22 | |
| Graham Net | 2.33 | 0.92 | 0.33 | 1.03 | 0.6 | |
| Working capital | 21.94M | 32.3M | 23.24M | 43.72M | 34.11M | |
| Tangible asset value | 55.84M | 31.55M | 22.39M | 42.86M | 33.2M | |
| Net current asset value | 55.61M | 31.36M | 22.24M | 42.71M | 33.08M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 2.43M | 3.96M | 4.74M | 2.54M | 563.5K | |
| Average payables | 3.77M | 5.38M | 6.05M | 6.04M | 5.45M | |
| Average inventory | 10.67M | 12.57M | 14.2M | 16.95M | 18.35M | |
| Days sales outstanding | 114.32 | 394.7 | 77.1 | 84.45 | 0 | |
| Days payables outstanding | 367.44 | 228.99 | 177.18 | 444.22 | 115.74 | |
| Days of inventory on hand | 1.03K | 461.21 | 480.6 | 1.28K | 464.9 | |
| Receivables turnover | 0.79 | 0.23 | 1.17 | 1.07 | 0 | |
| Payables turnover | 0.24 | 0.39 | 0.51 | 0.2 | 0.78 | |
| Inventory turnover | 0.09 | 0.2 | 0.19 | 0.07 | 0.19 | |
| ROE | -0.17 | -0.42 | -0.33 | -0.25 | -0.25 | |
| Capex per share | -0.01 | 0 | -0.01 | -0.01 | -0.01 |
BIOS.ST Frequently Asked Questions
What is Bioservo Technologies AB (publ) stock symbol ?
Bioservo Technologies AB (publ) is a SE stock and trading under the symbol BIOS.ST
What is Bioservo Technologies AB (publ) stock quote today ?
Bioservo Technologies AB (publ) stock price is $0.016 today.
Is Bioservo Technologies AB (publ) stock public?
Yes, Bioservo Technologies AB (publ) is a publicly traded company.
Company Profile
- Volume Average 2.51M
- Market Capitalization 1.41M
- Employee 20
- CEO Mr. Petter Backgren
- Headquarters Kista,SE
- IPO Date 2017-05-22
-
Website
https://www.bioservo.com 
Bioservo Technologies AB (publ) develops and sells wearable muscle strengthening systems worldwide. It offers Ironhand, a robotic grip that strengthens gloves, and Carbonhand that provides enhanced hand function. The company's products have applications in logistics, warehousing, construction, and healthcare sectors, as well as used in pre-assembly and assembly tasks. Bioservo Technologies AB (publ) was incorporated in 2003 and is based in Kista, Sweden.
